相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial
Meili Cai et al.
DIABETES OBESITY & METABOLISM (2022)
New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
W. Timothy Garvey
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
Binayak Sinha et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review
Reem Magzoub et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2022)
Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition
Jacob E. Pruett et al.
BIOLOGY OF SEX DIFFERENCES (2022)
Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial
Jiaqi Zhang et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor
Jelena Marinkovic-Radosevic et al.
WORLD JOURNAL OF DIABETES (2021)
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Silvio E. Inzucchi et al.
DIABETES CARE (2021)
Effects of metformin on body weight in polycystic ovary syndrome patients: model-based meta-analysis
Xiao Chen et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)
Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome
Jacob E. Pruett et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The Safety and Efficacy of Canagliflozin in Women with Polycystic Ovary Syndrome: A Randomized Control Trial
Meili Cai et al.
DIABETES (2021)
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial
Susanne Tan et al.
DIABETES OBESITY & METABOLISM (2021)
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome
Karen E. Elkind-Hirsch et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Effects of Sodium-Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice
Dominique Croteau et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes
Binayak Sinha et al.
JGH OPEN (2021)
Fournier's gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials
Giovanni Antonio Silverii et al.
DIABETES OBESITY & METABOLISM (2020)
Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis
Humaira Hussein et al.
DIABETES OBESITY & METABOLISM (2020)
Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease
Alexandra Chadt et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2020)
A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Mohammed Altigani Abdalla et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2020)
Impact of mitochondrial DNA copy number and displacement loop alterations on polycystic ovary syndrome risk in south Indian women
Tumu Venkat Reddy et al.
MITOCHONDRION (2019)
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study
Zeeshan Javed et al.
CLINICAL ENDOCRINOLOGY (2019)
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
Tadashi Toyama et al.
DIABETES OBESITY & METABOLISM (2019)
A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions
Wendy L. Bennett et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Yi Han et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2019)
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Carlo Garofalo et al.
MEDICINA-LITHUANIA (2019)
Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events
Milton Packer
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
Qingmiao Shao et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
Habib Yaribeygi et al.
LIFE SCIENCES (2019)
DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY
Simona Ferjan et al.
ENDOCRINE PRACTICE (2018)
Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet
Susumu Takagi et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
A Single Bout of Electroacupuncture Remodels Epigenetic and Transcriptional Changes in Adipose Tissue in Polycystic Ovary Syndrome
Milana Kokosar et al.
SCIENTIFIC REPORTS (2018)
Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes
Molly G. Minze et al.
CURRENT DIABETES REVIEWS (2018)
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
Dandan Li et al.
DIABETES OBESITY & METABOLISM (2017)
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
Per Lundkvist et al.
DIABETES OBESITY & METABOLISM (2017)
Ultrasonographic evaluation of intra-abdominal fat distribution and study of its influence on subclinical atherosclerosis in women with polycystic ovarian syndrome
Priyadarshini Tripathy et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2017)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis
A. L. L. Rocha et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2017)
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
Javad Habibi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Heidi Storgaard et al.
PLOS ONE (2016)
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside
Sunder Mudaliar et al.
DIABETES CARE (2015)
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition
Anne L. Peters et al.
DIABETES CARE (2015)
Pregnancy complications in women with polycystic ovary syndrome
Stefano Palomba et al.
HUMAN REPRODUCTION UPDATE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Metabolic risk in PCOS: phenotype and adiposity impact
Lisa J. Moran et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2015)
Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
T. Sathyapalan et al.
SCIENTIFIC REPORTS (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats
Naoki Kojima et al.
PHYSIOLOGICAL REPORTS (2015)
Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome
Poli Mara Spritzer et al.
REPRODUCTION (2015)
Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena
Mariangela Rondanelli et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2014)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease
Alison J. Dawson et al.
CLINICAL ENDOCRINOLOGY (2014)
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
Mojca Jensterle Sever et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome
Carly E. Kelley et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo et al.
DIABETES CARE (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome
Evanthia Diamanti-Kandarakis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome
Alessandro D. Genazzani et al.
GYNECOLOGICAL ENDOCRINOLOGY (2008)
Heritability of polycystic ovary syndrome in a Dutch twin-family study
J. M. Vink et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome
JC Lo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Changes in glucose tolerance over time in women with polycystic ovary syndrome: A controlled study
RS Legro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome
T Apridonidze et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome
DA Ehrmann et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS
MD Kahsar-Miller et al.
FERTILITY AND STERILITY (2001)
分享论文
